SCHEMBL321923

SCHEMBL321923

CCOC(=O)C(C)=Cc1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
NPSR1 Q6W5P4 4/20 0.57
LMNA P02545 3/20 0.57
S1PR4 O95977 1/20 0.57
S1PR1 P21453 1/20 0.57
MAPK1 P28482 1/20 0.57
CYP2C9 P11712 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C19 P33261 1/20 0.53
ALDH1A1 P00352 5/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
TRPA1 O75762 1/20 0.50
GAA P10253 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
HPGD P15428 2/20 0.46
HTT P42858 1/20 0.46
ATM Q13315 1/20 0.46
HDAC3 O15379 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14358911 1.00 MAPT (0.57) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL321922 1.00 MAPT (0.57) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL3609471 0.88 MAPT (0.58) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL3609468 0.88 MAPT (0.58) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL7651650 0.86 KMT2A (0.76) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL12035802 0.86 KMT2A (0.57) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL5617201 0.86 KMT2A (0.57) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL7030290 0.86 KMT2A (0.76) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL10564181 0.86 MAPT (0.57) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL10885404 0.86 MAPT (0.57) MAPTMEN1KMT2ANPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590963-B1 (3-METHYLPYRROLIDIN-3-YL)METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-12-03 EP disclosed
US-8507535-B2 Methyl-pyrrolidine ether derivatives HOFFMANN-LA ROCHE INC. (US) 2013-08-13 US disclosed
EP-2590963-A1 (3 -METHYLPYRROLIDIN- 3 - YL) METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2013-05-15 EP disclosed
WO-2012004207-A1 (3 -METHYLPYRROLIDIN- 3 - YL) METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-01-12 WO disclosed
US-20120010212-A1 METHYL-PYRROLIDINE ETHER DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010212-A1 METHYL-PYRROLIDINE ETHER DERIVATIVES OPRM1, OPRK1, OPRD1 MAPT 1088/4885MEN1 4677/4885KMT2A 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.